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Sir, 
The anti-convulsant drug carbamazepine may induce ge-
neralized exanthema or, less frequently, severe cutaneous 
eruptions, such as hypersensitivity syndrome or toxic 
epidermal necrolysis. The development of psoriasiform 
eruptions and the exacerbation of pre-existing psoriasis 
have been recognized as common adverse reactions to 
beta-blockers, lithium and antimalarials (1). Additional 
causative drugs include angiotensin converting enzyme 
inhibitor, indomethacin, progesterone, and lipid-lowering 
drugs, such as gemfibrozil (2). Drug-induced alopecia 
presents as a diffuse, non-scarring loss of hair that is often 
reversible upon discontinuation of the drug. The drugs as-
sociated with telogen effluvium include beta-blockers (3), 
angiotensin converting enzyme, oral contraceptives, anti-
thyroid medications, anticoagulants and anticonvulsant 
(4). We report here a case of a 52-year-old woman who 
experienced diffuse hair loss and a palmoplantar psoria-
siform eruption apparently due to carbamazepine.
CASE REPORT
A 52-year-old woman was referred to our dermatology 
clinic because of diffuse hair loss and psoriasiform er-
uptions on her hands and feet. She had no past or family 
history of psoriasis, alopecia, or other skin disorders. 
There was no evidence of dermatitis, allergic reaction, 
or other causes for hair loss and psoriasiform eruption. 
She was diagnosed with an acoustic schwannoma 2 
months previously and had been taking carbamaze-
pine (200 mg, 3 times/day) for 3 months due to severe 
facial pain. The psoriasiform eruptions on her palms 
and soles started one month after administration of 
carbamazepine, and remarkable hair loss occurred one 
month after the appearance of the eruptions. Physical 
examination showed thick hyperkeratotic plaques on 
the palmoplantar areas and diffuse hair loss on the 
scalp (Fig. 1). A hair-pull test demonstrated that hairs 
could be extracted easily. Since carbamazepine was 
suspected as one of the inciting agents, the dosage of 
carbamazepine was reduced to 200 mg once/day. The 
psoriasiform eruptions began to improve one week 
after tapering the drug without any treatment. The pal-
moplantar lesions also improved (Fig. 2) and the hair 
loss began to stop 4 weeks after decreasing the dose. 
Two months later, she underwent surgical operation 
for the acoustic schwannoma. The eruptions cleared 
completely and spontaneous hair regrowth was shown 
after discontinuing medication.
DISCUSSION
A causative relationship between a drug and associated 
adverse reactions is based primarily on experience and 
observation. The following three factors are important 
in supporting the diagnosis of a drug reaction: first, 
the adverse reaction occurs after drug administration; 
secondly, as long as the patient continues to take the 
drug, the adverse reaction resists conventional treat-
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Fig. 1. (A) Hyperkeratotic scaly plaques of the palm. (B) Thick hyperkeratotic 
yellow-coloured plaques of the sole. (C) Diffuse hair loss on the scalp.
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ment; and thirdly, the adverse reaction improves within 
days of ceasing the drug. Above all, the rechallenge 
test more definitely supports the presence of a drug 
reaction, but a drug rechallenge is difficult to perform 
in practice (5). Since the suspected drug reactions in 
our patient improved immediately after the tapering 
of medication, carbamazepine should be considered a 
possible causative agent of hair loss and palmoplantar 
psoriasiform eruptions. 
Although many new anticonvulsants have been in-
troduced recently, carbamazepine has been widely used 
for many years in the treatment of epilepsy and other 
neurological diseases. Carbamazepine-induced hair loss 
has been reported as occurring at various rates. Phillans & 
Woods (4) reported 177 cases of carbamazepine-induced 
alopecia. A double-blind, multi-centre trial, the aim of 
which was to compare carbamazepine and valproic acid, 
showed that hair loss or changes in hair texture were seen 
in 6% of the patients treated with carbamazepine (6). 
Kohno et al. (7) reported that the frequency of carbama-
zepine-induced hair loss was below 2%. They suggested 
carbamazepine could induce two patterns of hair loss: 
anagen effluvium, in which the hair loss starts within one 
week, and telogen effluvium, in which it starts after 2–3 
months. The type of hair loss in our patient seemed to be 
telogen effluvium because the hair loss started 2 months 
after initial administration of the medication. 
It is estimated that about 3% of patients receiving 
carbamazepine will develop a cutaneous adverse 
reaction, including erythematous, morbilliform, or 
urticarial rashes. Recently, human herpes virus-6 has 
been reported to have a potential role in carbamazepine-
induced hypersensitivity syndrome (8). Case reports of 
psoriasiform eruptions induced by this drug are limited 
(2, 9). By contrast, Smith et al. (10) reported that carba-
mazepine may be a therapeutic option for the treatment 
of HIV-positive psoriatic patients. The mechanisms of 
carbamazepine to induce or clear psoriasiform eruption 
are not known yet. Carbamazepine inhibits the uptake 
of noradrenaline and blocks cyclic AMP-mediated cal-
cium influx (11). Carbamazepine or its metabolites have 
been suggested to play a role in the clearing of psoriasis 
through an immune-modulating effect. We also think 
that the mechanism is associated with adrenergic inflam-
mation or the release of neuropeptides, which influence 
psoriasiform eruption. Physicians should recognize 
that this drug might produce psoriasiform eruptions or 
aggravate pre-existing psoriasis. Moreover, this is the 
first report of this type of case, in which carbamazepine 
induced psoriasiform eruptions and hair loss at the same 
time. We report that carbamazepine, which has been 
widely used, might induce hair loss and psoriasiform 
eruption concomitantly.
The authors declare no conflicts of interest.
REFERENCES
1. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. 
Drugs in exacerbation of psoriasis. J Am Acad Dermatol 
1986; 15: 1007–1022.
2. Brenner S, Wolf R, Landau M, Politi Y. Psoriasiform erup-
tion induced by anticonvulsants. Isr J Med Sci 1994; 30: 
283–286.
3. England JR, England JD. Alopecia and propranolol therapy. 
Aust Fam Physician 1982; 11: 225–226.
4. Phillans PL, Woods DJ. Drug-associated alopecia. Int J 
Dermatol 1995; 34: 149–158.
5. Uetrecht J. Is it possible to more accurately predict which 
drug candidates will cause idiosyncratic drug reactions? 
Curr Drug Metab 2000; 1: 133–141.
6. Mattson RH, Cramer JA, Collins JF. A comparison of val-
proate with carbamazepine for the treatment of complex 
partial seizures and secondarily generalized tonic-clonic 
seizures in adults. N Engl J Med 1992; 327: 765–771.
7. Kohno Y, Ishii A, Shoji S. A case of hair loss induced by 
carbamazepine. Rinsho Shinkeigaku 2004; 44: 379–381.
8. Zeller A, Schaub N, Steffen I, Battegay E, Hirsch HH, 
Bircher AJ. Drug hypersensitivity syndrome to carbama-
zepine and human herpes virus 6 infection: case report and 
literature review. Infection 2003; 31: 254–256.
9. Brenner S, Golan H, Lerman Y. Psoriasiform eruption and 
anticonvulsant drugs. Acta Derm Venereol 2000; 80: 382.
10. Smith KJ, Decker C, Yeager J, Skelton HG, Baskin S. 
Therapeutic efficacy of carbamazepine in a HIV-1-positive 
patient with psoriatic erythroderma. J Am Acad Dermatol 
1997; 35: 851–854.
11. Kutt H, Paris-Kutt H. Carbamazepine. In: Woodbury DM, 
Penry JK, Pippenger CE, editors. Antiepileptic drugs. 2nd 
edn. New York: Raven Press, 1982; p. 453–547.
Fig. 2. (A, B) Patient followed up 2 weeks after decreasing the dose of 
carbamazepine. Palmoplantar lesions began to improve one week after 
tapering the drug, with no further treatment. 
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